These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 11642523)

  • 41. Botox therapy for ischemic digits.
    Neumeister MW; Chambers CB; Herron MS; Webb K; Wietfeldt J; Gillespie JN; Bueno RA; Cooney CM
    Plast Reconstr Surg; 2009 Jul; 124(1):191-201. PubMed ID: 19568080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fish-oil dietary supplementation in patients with Raynaud's phenomenon: a double-blind, controlled, prospective study.
    DiGiacomo RA; Kremer JM; Shah DM
    Am J Med; 1989 Feb; 86(2):158-64. PubMed ID: 2536517
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M; Cobankara V; Akpolat T
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Office evaluation and treatment of Raynaud's phenomenon.
    Bolster MB; Maricq HR; Leff RL
    Cleve Clin J Med; 1995; 62(1):51-61. PubMed ID: 7859402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study.
    Denton CP; Howell K; Stratton RJ; Black CM
    Clin Exp Rheumatol; 2000; 18(4):499-502. PubMed ID: 10949727
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is iloprost effective in secondary Raynaud's phenomenon?
    Lustig N; Rada G
    Medwave; 2015 Mar; 15(2):e6082. PubMed ID: 25826330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhaled iloprost for the treatment of Raynaud's phenomenon.
    Pakozdi A; Howell K; Wilson H; Fox S; Gonzalez L; Black CM; Denton CP
    Clin Exp Rheumatol; 2008; 26(4):709. PubMed ID: 18799113
    [No Abstract]   [Full Text] [Related]  

  • 48. Occlusive digital artery disease in patients with Raynaud's phenomenon.
    Zweifler AJ; Trinkaus P
    Am J Med; 1984 Dec; 77(6):995-1001. PubMed ID: 6334442
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Methylphenidate and secondary Raynaud's phenomenon].
    Iglesias Otero M; Portela Romero M; Bugarín González R; Ventura Victoria MA
    Semergen; 2013 Sep; 39(6):330-4. PubMed ID: 24034762
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Raynaud's phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi's sarcoma.
    Reiser M; Bruns C; Hartmann P; Salzberger B; Diehl V; Fätkenheuer G
    Eur J Clin Microbiol Infect Dis; 1998 Jan; 17(1):58-60. PubMed ID: 9512187
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discontinuing long-term Iloprost treatment for Raynaud's Phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study.
    Bali G; Schwantzer G; Aberer F; Kraenke B; Aberer E
    Acta Dermatovenerol Alp Pannonica Adriat; 2011; 20(1):13-21. PubMed ID: 21879200
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Coronary vasospasm-induced acute diastolic dysfunction in a patient with Raynaud's phenomenon.
    Tschöpe C; Westermann D; Steendijk P; Kasner M; Rudwaleit M; Schwimmbeck PL; Poller WC; Schultheiss HP
    Clin Res Cardiol; 2006 Jun; 95(6):344-8. PubMed ID: 16741592
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon.
    Khan F; Coffman JD
    Circulation; 1994 Mar; 89(3):1183-8. PubMed ID: 8124805
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud's phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA).
    Fraticelli P; Martino GP; Murri M; Mattioli M; Gabrielli A
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):173-178. PubMed ID: 28869415
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.
    Fregene A; Ditmars D; Siddiqui A
    J Hand Surg Am; 2009 Mar; 34(3):446-52. PubMed ID: 19258141
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cocaine-related peripheral vascular occlusive disease treated with iloprost in addition to anticoagulants and antibiotics.
    Mazzone A; Giani L; Faggioli P; Pichini S; Pacifici R
    Clin Toxicol (Phila); 2007; 45(1):65-6. PubMed ID: 17357385
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon.
    Marasini B; Massarotti M; Bottasso B; Coppola R; Del Papa N; Maglione W; Comina DP; Maioli C
    Scand J Rheumatol; 2004; 33(4):253-6. PubMed ID: 15370722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.